Abstract. It is well established that spasm of an arterial and venous graft conduit may occur during harvesting or after coronary artery bypass grafting (CABG). The antivasoconstrictor effect of levcromakalim and rilmakalim, K + channel openers (KCOs), was studied in isolated human internal mammary artery (HIMA) and human saphenous vein (HSV) prepared for CABG. HIMA and HSV rings were contracted by electrical field stimulation (EFS, 20 Hz ) or with exogenous noradrenaline (NA). Levcromakalim induced a concentration-dependent and equipotent inhibition of contraction of HIMA and HSV preconstricted by EFS and exogenoulsy applied NA, while rilmakalim produced a stronger inhibition of EFS-than NA-evoked contractions. Glibenclamide, a selective ATP-sensitive K + channel (K ATP channel) blocker, significantly antagonized levcromakalim-induced inhibition of EFS-and NA-evoked contractions, as well as rilmakalim-induced inhibiton of EFS-evoked contractions on HIMA and HSV. However, glibenclamide failed to antagonize rilmakalim-induced inhibition of NA-evoked contractions. The results suggest that the antivasoconstrictor effect of levcromakalim occurs postsynapticaly by the opening K ATP channels in the vascular smooth muscle cells. They also suggest that the effect of rilmakalim on EFSevoked contractions involves K ATP channels located pre-synaptically. However, the mechanism by which rilmakalim inhibits NA-evoked contraction seems to be K ATP channel independent and warrants further elucidation.
Introduction
The human internal mammary artery (HIMA) and human saphenous vein (HSV) are the vessels of choice for coronary artery bypass grafting (CABG). Spasm of arterial and venous graft conduit may occur during harvesting or immediately following CABG (1 -3) . The mechanism of graft spasm is not yet elucidated, although physical (mechanical manipulation, temperature changes), and humoral factors (circulating vasoconstrictor substances) have been evoked (4, 5) . Vasodilatators such as papaverine, calcium antagonists, and long-acting nitrates are usually added locally before grafting. However they seem to be more effective in suppression than prevention of graft spasm (6) . K + channel openers (KCOs), a new class of vasodilatators (pinacidil, levcromakalim, rilmakalim, diazoxide, etc.), was found to exert their effects on vascular smooth muscles by opening ATP-sensitive K + channels (K ATP channels) that produce hyperpolarization of the vascular cell membrane leading to vasorelaxation (7, 8) . K ATP channels have been identified in other tissues such as cardiac and skeletal muscle, smooth muscle, neurons, and pancreatic b cells where they couple the metabolic state of a cell to its electrical activity (9 -11) . In addition, KCOs were found to modulate vascular tone by reducing neurotransmitter release from presynaptic nerve terminals (12 -14) . We have provided evidence that the antivasoconstrictor action of pinacidil on the neurogenic contractions of the rabbit portal vein is associated with presynaptically located K ATP channels (15) .
Taking into consideration that the search for drugs capable of modifying blood flow through human vascular grafts is warranted, the present study was designed to examine the antivasoconstrictor effects of levcromakalim and rilmakalim on the HIMA and HSV, as well as the possible contribution of pre-and post-synaptically located K ATP channels. The HIMA and HSV were contracted by exogenously applied noradrenaline (NA) through the involvement of postsynaptic a -adrenoceptors and by endogenously released NA during electrical field stimulation (EFS) that involves presynaptic mechanisms.
Materials and Methods
The HIMA (n = 71) and HSV (n = 66) segments were collected from patients undergoing CABG suffering from coronary artery disease. The patients were informed in detail about the purpose of the investigation and had given the written consent for the excision of the preparations by their free will. The vessels were excised within 10 min of clamping the blood flow and placed in cold (4°C) Krebs-Ringer-bicarbonate solution. After excision, the vessels were immediately transported to the laboratory.
Vascular preparations
The HIMA and HSV segments were dissected free from connective tissue. After removal of endothelium, rings (3 mm) were mounted between two stainless-steel triangles in an organ bath containing 15 ml Krebs-Ringerbicarbonate solution (37°C, pH of 7.4), aerated with 95% O 2 and 5% CO 2 . One of the triangles was attached to a displacement unit, allowing fine adjustment of tension, and the other was connected to the isometric transducer (K30; Hugo Sachs, Freiburg, Germany).
The preparations were allowed to equilibrate for 60 min. During this period, the vessels were washed with a fresh buffer solution every 15 min.
Experimental procedure
Contraction of the HIMA and HSV evoked by EFS: Intramural nerves were stimulated using two platinum wire electrodes. The repetitive transmural EFS was carried out at 20 Hz with square wave pulses of 0.3-ms duration and supramaximal voltage. Trains of pulses of 3-s duration were delivered at 2-min intervals from a Grass S44 electronic stimulator (15) .
The preparations were allowed to stabilize for at least 30 min (until twitch responses became consistent) before addition of drugs. Concentration-response curves were constructed by addition of KCOs directly into the bathing solution in a cumulative way, taking the amplitude of the response measured immediately before addition of a drug as a control contraction (100%). Higher concentration of KCO was added only when the previous concentration had produced an equilibrium response.
In separate experiments, after twitch responses became consistent, the potassium channel antagonist (glibenclamide) was added into the bathing solution at least 20 min before exposure to KCO. Addition of glibenclamide (1 mM) did not modify the basal contractions of HSV (n = 4) and HIMA (n = 4) evoked by EFS. The amplitude of the response measured immediately before addition of KCOs was taken as the control (100%).
The confirmation that EFS-induced contraction is mediated by neurotransmitter release from sympathetic nerves was obtained by addition of tetrodotoxin or phentolamine to the bathing solution, 20 min before applying EFS.
Contraction of the HIMA and HSV evoked by exogenous NA: In a separate series of experiments, the vascular preparations were challenged repeatedly, for 2 min at 60-min (HSV) and 90-min (HIMA) intervals, with NA (10 mM) to produce contractions similar in shape (maximal amplitude and slope) to those evoked by EFS. After achieving the maximal amplitude of the phasic contraction induced by exogenous NA, the vascular preparation was washed to prevent the development of sustained (tonic) contraction. KCOs were added into the medium for 10 min, and the preparation was rechallanged to NA. The control exposure to NA was taken as 100% response. The antivasoconstrictor effect of levcromakalim and rilmakalim was then investigated in the presence of glibenclamide added to the preparation 20 min prior to KCOs. Glibenclamide alone did not modify the basal contractions of HSV or HIMA (n = 4 for both) evoked by exogenous NA.
Treatment of data and statistics
The results are expressed as the means ± standard error of the mean (S.E.M.); n refers to the number of experiments. The least squares method was used for calculating linear regression. The concentration of rilmakalim or levcromakalim producing 50% of the maximum response (EC 50 ) was determined graphically for each curve by linear interpolation. The EC 50 values are presented as pEC 50 (-log EC 50 ). Statistical difference between means was determined by Student's t-test, and a P value <0.05 was considered statistically significant.
Drugs
The following drugs were used: rilmakalim (gift from Dr. I. Kocic, Gdanjsk); levcromakalim (gift from Dr. T. Hamilton, SmithKline Beecham Pharmaceuticals, Betchwort, UK); noradrenaline hydrochloride, tetrodotoxin, phentolamine hydrochloride, and glibenclamide, (Sigma Chemical Co., St. Louis, MO, USA). Levcromakalim was dissolved in 70% v / v ethanol with further dilution in distilled water before use. Rilmakalim was dissolved in ethanol and dimethyl sulphoxide (1:1) and further diluted with distilled water. Glibenclamide was dissolved in polyethylene glycol. Noradrenaline was dissolved in dilute acid solution (0.1 N HCl). Previous experiments showed that the solvents used had no effects on preparations at the concentrations applied.
All drugs were added directly to the bath in a volume of 100 m L and the concentrations given are the calculated final concentrations in the bath solution.
Results

Effects of tetrodotoxin and a -adrenoceptor blockade on EFS induced contractions
Tetrodotoxin (1 mM) abolished the EFS evoked contraction of HSV (n = 4) and HIMA (n = 4). Phentolamine (1 mM) reduced the EFS evoked contraction of HSV (88 ± 3%, n = 4), and HIMA (87 ± 2%, n = 5). Data are not shown.
Effects of levcromakalim and rilmakalim on EFS evoked contractions and exogenous NA-induced contractions Figure 1 shows the antivasoconstrictor effects of levcromakalim and rilmakalim on EFS (20 Hz ) evoked contractions and exogenous NA (10 m M)-induced contractions in the HSV ( ( Fig. 1: C and D) .
Levcromakalim (1 nM -30 mM) induced a concentration-dependent inhibition of both neurogenic contractions, and contractions evoked by exogenous NA of the HSV with pEC 50 values of 6.4 ± 0.1 (maximal response 89 ± 2%, n = 7) and 6.3 ± 0.1 (maximal response 86 ± 2%, n = 6), respectively (Fig. 1A) . The difference between the pEC 50 values was not statistically significant (P>0.05). Rilmakalim (0.3 nM -30 m M) induced a concentration-dependent inhibition of neurogenic contractions and contractions evoked by exogenous NA of the HSV with pEC 50 values of 6.8 ± 0.1 (maximal response, 80 ± 2%, n = 6) and 6.1 ± 0.1 (maximal response, 73 ± 2%, n = 6), respectively (Fig. 1B) . The difference between the pEC 50 values was statistically significant (P<0.05). Figures 1C and 1D show the effect of levcromakalim and rilmakalim on neurogenic and exogenous NAinduced contractions in the HIMA. Levcromakalim (0.1 nM -30 m M) produced a concentration-dependent inhibition of neurogenic contractions (maximal response, 77 ± 2%, n = 7) and contractions evoked by exogenous NA (maximal response, 71 ± 2%, n = 8) of the HIMA (Fig. 1C) . The pEC 50 values were not statistically significant (6.2 ± 0.3 and 5.8 ± 0.3, respectively; P>0.05) (Fig. 1C) . The difference between the pEC 50 values of rilmakalim (1 nM -100 m M) effects on the neurogenic (maximal response, 79 ± 2%, n = 8) contractions and contractions evoked by exogenous NA (maximal response, 63 ± 3%, n = 8) in the HIMA was statistically significant (6.9 ± 0.1 and 6.0 ± 0.1, respectively; P<0.05, Fig. 1D ).
Effects of glibenclamide, a selective K ATP antagonist on the inhibition of neurogenic contractions and contractions evoked by exogenous NA produced by KCOs Figure 2 illustrates the effect of glibenclamide on the inhibition of neurogenic contractions and contractions evoked by exogenous NA produced by levcromakalim and rilmakalim on the HSV (Fig. 2: A and B) and on the 
HIMA (Fig. 2: C and D).
Glibenclamide (1 mM) significantly antagonized the inhibitory action of levcromakalim (10 m M) both on the neurogenic contractions (% of control contraction: 11 ± 1% in the absence vs 74 ± 1% in the presence of glibenclamide, P<0.01, n = 5) and on the contractions evoked by exogenous NA (% of control contraction: 14 ± 2% in the absence vs 70 ± 2% in the presence of glibenclamide, P<0.01, n = 5) of the HSV (Fig. 2A) .
The inhibitory action of rilmakalim (10 m M) on the neurogenic contractions of HSV was significantly antagonized by 1 mM of glibenclamide (% of control contraction: 22 ± 2% in the absence vs 85 ± 2% in the presence of glibenclamide, P<0.01, n = 7), as shown in Fig. 2B . However, glibenclamide (1 mM) failed to antagonize the inhibitory action of rilmakalim (10 m M) on contractions of HSV evoked by exogenous NA (% of control contraction: 27 ± 2% in the absence vs. 28 ± 2% in the presence of glibenclamide, P>0.05, n = 7, Fig. 2B ). In addition, glibenclamide (1 m M) did not antagonize the inhibitory action of 0.1 m M of rilmakalim (% of control contraction: 74 ± 2% in the absence vs 76 ± 3% in the presence of glibenclamide, P>0.05, n = 4) or 1 m M of rilmakalim (% of control contraction: 44 ± 2% in the absence vs 46 ± 2% in the presence of glibenclamide, P>0.05, n = 5) on the NA-evoked contractions (data not shown).
In the HIMA, glibenclamide (1 mM) antagonized the inhibitory action of levcromakalim and rilmakalim on the contractions evoked by EFS and exogenous NA similarly as in the HSV (Fig. 2: C and D) . The inhibitory action of levcromakalim (10 m M) was antagonized by glibenclamide both on the neurogenic contractions (% of control contraction: 23 ± 2% in the absence vs 85 ± 2% in the presence of glibenclamide, P<0.01, n = 5) and on the contractions evoked by exogenous NA (% of control contraction: 30 ± 2% in the absence vs 82 ± 2% in the presence of glibenclamide, P<0.01, n = 5), as shown in Fig. 2C .
Glibenclamide (1 mM) significantly antagonized the inhibitory action of rilmakalim (10 m M) on the neurogenic contractions (% of control contraction: 22 ± 1% in the absence vs 85 ± 2% in the presence of glibenclamide, P<0.01, n = 6, Fig. 2D ). In contrast, glibenclamide (1 m M) failed to antagonize the inhibitory action of rilmakalim (10 mM) on the contractions evoked by exogenous NA (% of control contraction: 39 ± 2% in the absence vs 41 ± 3% in the presence of glibenclamide, P>0.05, n = 7, Fig. 2D ). Glibenclamide (1 mM) did not antagonize the inhibitory action of 0.1 m M of rilmakalim (% of control contraction: 82 ± 2% in the absence vs 85 ± 2% in the presence of glibenclamide, P>0.05, n = 4) or 1 m M of rilmakalim (% of control contraction: 53 ± 2% in the absence vs 55 ± 2% in the presence of glibenclamide, P>0.05, n = 4) on the NA-evoked contractions (data not shown).
Discussion
It is now well established that EFS of perivascular nerve terminals on isolated blood vessels releases neurotransmitters and co-transmitters such as noradrenaline, adenosine 5'-triphosphate, and acetylcholine to induce vascular contractions (16, 17) . To validate the effect of transmural EFS on the isolated blood vessels, we applied tetrodotoxin in 1 m M concentration that selectively paralyzes nerve endings (18) . The confirmation of the neurogenic nature of the contraction induced by EFS in our experiments was obtained by 100% inhibition of EFSinduced contraction of the HIMA and HSV by tetrodotoxin. In order to further define the site of action / mechanisms by which EFS induces contraction of human grafts, we used phentolamine. A significant reduction of EFS-induced contraction by phentolamine (>80%) indicates that NA released from perivascular sympathetic nerve endings of vascular preparations acts on vascular, postjunctional a-adrenoceptors.
Levcromakalim concentration-dependently inhibited both the neurogenic contraction and the contraction evoked by exogenous NA on HIMA and HSV. The fact that there was no significant difference in the inhibition of the neurogenic and NA-induced contraction suggests that the antivasoconstrictor effect of levcromakalim occurs postsinaptically and that it involves the activation of K + channels located on the vascular tissue. This finding is in line with results of Standen et al. (7) and Nelson and Quayle (8) who reported that KCOs inhibit the NA-induced vasoconstrictor response on various vascular smooth muscle preparations by opening K + channels located on the postsynaptic membrane. However, we observed that rilmakalim produced a more potent inhibition of the neurogenic contraction of the HIMA and HSV than the contractions induced by exogenously applied NA. Differences in the antivasoconstrictor effects of levcromakalim and rilmakalim on the contractions of the HSV and HIMA evoked by EFS and exogenous NA suggest that KCOs may have different sites/ mechanisms of antivasoconstrictor action. This assumption is in line with our previous study on the antivasoconstrictor effect of pinacidil and levcromakalim on the rabbit portal vein (15) .
To further evaluate this possibility, glibenclamide, a K ATP channel blocker, was introduced. The concentration of glibenclamide we used (1 mM) was reported to be highly selective for vascular, pancreatic, and neuronal K ATP channels (19) . In higher concentrations, glibencl-amide was found to modulate other ion channels (20) such as chloride channels (30 mM) and L-type Ca 2+ channels (10 mM), as well as the kinetics of calcium release from the sarcoplasmic reticulum (concentrations >1 mM; refs. 14, 20). In our experiments, glibenclamide did not modify the basal contractions evoked by EFS, suggesting that at 1 mM concentration glibenclamide does not interfere with neurotransmitter release. This is in line with earlier reports showing that glibenclamide in much higher concentrations (at least 30 m M) modulate neurotransmitter release (13, 20) . In the present study glibenclamide antagonized the levcromakalim-induced inhibition of contractions on the HIMA and HSV evoked by EFS as well as the contraction evoked by exogenous NA. This further confirms that the antivasoconstrictor effect of levcromakalim is mediated by the opening of vascular K ATP channels. Moreover, the concentration of glibenclamide we used minimizes the possibility that the antagonistic effect of glibenclamide on the antivasoconstrictor effect of levcromakalim involves mechanisms other than K ATP blockade. This result corresponds well with the reports of Edwards and Weston (21) and with our previous reports on KCOs and the HIMA (22) and the rabbit portal vein (15) .
Glibenclamide used in the same concentration also antagonized the antivasoconstrictor effect of rilmakalim on the neurogenic contractions. K ATP channels have been identified in noradrenergic nerve terminals of the rat cortex (14, 23, 24) , GABAergic terminals of rat substantia nigra (25 -27) and on the mouse cholinergic motor nerve endings (28) . These channels seem to be involved in the control of transmitter release when the energy content of the nerve terminal is low as in ischemia, hypoxia, or hypoglycemia (28, 12 Rb efflux, supporting a role for K ATP channels in the modulation of transmitter release. Therefore, it seems reasonable to propose that glibenclamide sensitive K ATP channels, located presynaptically, could be involved in the antivasoconstrictor effect of rilmakalim on neurogenically but not NA-induced contraction of the HSV and HIMA.
Nonetheless glibenclamide did not modify the effect of rilmakalim (10 mM) on the contraction induced by exogenously applied NA. The failure of glibenclamide to antagonize rilmakalim-induced inhibition of NAevoked contractions was additionally confirmed in two other series of experiments using lower concentrations of rilmakalim (0.1 and 1 mM). These results imply that the antivasoconstrictor effect of rilmakalim on NAevoked contraction of HIMA and HSV involves vascular -transients in microvascular endothelial cells. We have also shown that pinacidil (³10 m M) relaxes HIMA rings bathed by a medium containing 100 mM K + with a maximum response >80% (22) . Although the mechanism by which rilmakalim prevents NA evoked contraction of HIMA and HSV is beyond the scope of this paper and necessitates further elucidation, we may speculate that modulation of the intracellular signaling pathways by rilmakalim may be involved.
Our results show that levcromakalim and rilmakalim, are potent antivasoconstrictor agents on the HSV and HIMA and that they can be considered as potential drugs in prevention of the bypass graft spasm. They also suggest that the site of action and the mechanisms underlying the antivasoconstrictor action of levcromakalim and rilmakalim are not the same. The effect of levcromakalim occurs postsynaptically by the opening K ATP channels in the vascular smooth muscle cells. However, it seems that the effect of rilmakalim on EFS-evoked contractions involves K ATP channels located pre-synaptically. The exact mechanism / s by which rilmakalim anatgonizes NA-evoked contractions of HIMA and HSV warrants further elucidation.
